M A Kromhout1, N Rius Ottenheim2, E Giltay2, M E Numans3, W P Achterberg3. 1. Leiden University Medical Centre, department of Public Health and Primary Care, V0-P, Postbus 9600, 2300 RC Leiden, the Netherlands. Electronic address: m.a.kromhout@lumc.nl. 2. Leiden University Medical Centre, department of Psychiatry, B1-P, Postbus 9600, 2300 RC, Leiden, the Netherlands. 3. Leiden University Medical Centre, department of Public Health and Primary Care, V0-P, Postbus 9600, 2300 RC Leiden, the Netherlands.
Abstract
BACKGROUND: The consumption of caffeine has well known effects on the behavior and sleep of healthy adults. Behavioral symptoms and sleeping difficulties are common in patients with dementia which may be affected by caffeine consumption. This systematic review examines the association between caffeine intake and neuropsychiatric symptoms in patients with dementia. METHODS: In January 2019 an extensive search was conducted in Medline (PubMed), Embase, Emcare, Cochrane, PsychInfo, Web of Science and gray literature. Studies were included when they: i) investigated patients diagnosed with dementia, ii) reported neuropsychiatric symptoms, iii) used caffeine or coffee consumption as an intervention, and iv) reported associations between caffeine or coffee consumption and neuropsychiatric symptoms. Studies were excluded when they also included participants without a diagnosis of dementia, or presented a review or expert opinion. Two reviewers independently rated the studies and reached consensus on the appraisal. RESULTS: Of the seven studies eligible for this review, four reported on sleeping difficulties and five on behavioral symptoms. There was no consistent effect of caffeine administration on neuropsychiatric symptoms: e.g., both high caffeine consumption and eliminating caffeine were associated with less apathy, the total Neuropsychiatric Inventory (Nursing Home) decreased after both coffee therapy and after eliminating caffeine, and both caffeine consumption and eliminating caffeine improved sleep. CONCLUSION: These findings suggest that caffeine can either induce or reduce neuropsychiatric symptoms in individual patients with dementia. Therefore, in these patients, caffeine consumption requires a prudent individualized approach and further research on the effects of caffeine on individual neuropsychiatric symptoms is required.
BACKGROUND: The consumption of caffeine has well known effects on the behavior and sleep of healthy adults. Behavioral symptoms and sleeping difficulties are common in patients with dementia which may be affected by caffeine consumption. This systematic review examines the association between caffeine intake and neuropsychiatric symptoms in patients with dementia. METHODS: In January 2019 an extensive search was conducted in Medline (PubMed), Embase, Emcare, Cochrane, PsychInfo, Web of Science and gray literature. Studies were included when they: i) investigated patients diagnosed with dementia, ii) reported neuropsychiatric symptoms, iii) used caffeine or coffee consumption as an intervention, and iv) reported associations between caffeine or coffee consumption and neuropsychiatric symptoms. Studies were excluded when they also included participants without a diagnosis of dementia, or presented a review or expert opinion. Two reviewers independently rated the studies and reached consensus on the appraisal. RESULTS: Of the seven studies eligible for this review, four reported on sleeping difficulties and five on behavioral symptoms. There was no consistent effect of caffeine administration on neuropsychiatric symptoms: e.g., both high caffeine consumption and eliminating caffeine were associated with less apathy, the total Neuropsychiatric Inventory (Nursing Home) decreased after both coffee therapy and after eliminating caffeine, and both caffeine consumption and eliminating caffeine improved sleep. CONCLUSION: These findings suggest that caffeine can either induce or reduce neuropsychiatric symptoms in individual patients with dementia. Therefore, in these patients, caffeine consumption requires a prudent individualized approach and further research on the effects of caffeine on individual neuropsychiatric symptoms is required.
Authors: Indira Paz-Graniel; Nancy Babio; Nerea Becerra-Tomás; Estefania Toledo; Lucia Camacho-Barcia; Dolores Corella; Olga Castañer-Niño; Dora Romaguera; Jesús Vioque; Ángel M Alonso-Gómez; Julia Wärnberg; J Alfredo Martínez; Luís Serra-Majem; Ramon Estruch; Francisco J Tinahones; Fernando Fernandez-Aranda; José Lapetra; Xavier Pintó; Josep A Tur; Antonio García-Rios; Aurora Bueno-Cavanillas; José J Gaforio; Pilar Matía-Martín; Lidia Daimiel; Vicente Martín Sánchez; Josep Vidal; Lucía Prieto-Sanchez; Emilio Ros; Cristina Razquin; Cristina Mestres; José V Sorli; Aida M Cuenca-Royo; Angel Rios; Laura Torres-Collado; Jessica Vaquero-Luna; Napoleon Pérez-Farinós; M Angeles Zulet; Almudena Sanchez-Villegas; Rosa Casas; M Rosa Bernal-Lopez; José Manuel Santos-Lozano; Xavier Corbella; David Mateos; Pilar Buil-Cosiales; Susana Jiménez-Murcia; Rebeca Fernandez-Carrion; Laura Forcano-Gamazo; Meritxell López; Miguel Ángel Sempere-Pascual; Anai Moreno-Rodriguez; Alfredo Gea; Rafael de la Torre-Fornell; Jordi Salas-Salvadó Journal: Eur J Nutr Date: 2020-10-30 Impact factor: 5.614